enerisant
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 11, 2014 (NCT04631276)
Timeline
Indications
Mechanism of action
- Histamine H3 receptorINVERSE AGONIST
HRH3 inverse agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03267303 | Phase 2 | Oct 31, 2017 | Taisho Pharmaceutical |
| NCT04631276 | Phase 1 | Dec 11, 2014 | Taisho Pharmaceutical |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Taisho Pharmaceutical | For profit | 2 | 2 | 2 | 2014 |
1 organizations
Page 1 / 1